Baxter/$BAX
1D1W1MYTD1Y5YMAX
Capital at risk
About Baxter
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
- Ticker
- $BAX
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 37,500
- Headquarters
- Deerfield, United States
- Website
- www.baxter.com
Baxter Metrics
BasicAdvanced
$12B
-
-$2.06
0.59
$0.20
0.17%
Price and volume
Market cap
$12B
Beta
0.59
52-week high
$30.00
52-week low
$15.73
Average daily volume
5.9M
Dividend rate
$0.20
Financial strength
Current ratio
1.946
Quick ratio
1.133
Long term debt to equity
1.428
Total debt to equity
1.564
Interest coverage (TTM)
3.19%
Profitability
EBITDA (TTM)
1,884
Gross margin (TTM)
35.88%
Net profit margin (TTM)
-9.27%
Operating margin (TTM)
8.12%
Effective tax rate (TTM)
-100.41%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
2.85%
Return on equity (TTM)
-14.37%
Valuation
Price to revenue (TTM)
1.049
Price to book
1.95
Price to tangible book (TTM)
-4.39
Price to free cash flow (TTM)
14.822
Free cash flow yield (TTM)
6.75%
Free cash flow per share (TTM)
1.577
Dividend yield (TTM)
0.86%
Forward dividend yield
0.17%
Growth
Revenue change (TTM)
5.36%
Earnings per share change (TTM)
570.93%
3-year revenue growth (CAGR)
-2.54%
10-year revenue growth (CAGR)
1.33%
3-year earnings per share growth (CAGR)
-28.51%
10-year earnings per share growth (CAGR)
-13.41%
3-year dividend per share growth (CAGR)
-44.34%
10-year dividend per share growth (CAGR)
-8.29%
What the Analysts think about Baxter
Analyst ratings (Buy, Hold, Sell) for Baxter stock.
Analyst projections of the future price of Baxter stock.
Bulls say / Bears say
Baxter raised its 2026 adjusted earnings guidance after second-quarter sales grew 5%, giving investors evidence that the turnaround is gaining traction. (Reuters)
Advanced Surgery, drug compounding and patient-support products are growing, while management expects its infusion-pump portfolio to improve in the second half. This gives Baxter several recovery drivers rather than relying on one product. (Investing.com, Morningstar)
Positive free cash flow and a stated target of roughly three times net leverage by year-end could lower financial pressure and create more room for investment once debt reduction is delivered. (VectorShift Research, Baxter North America)
The Novum IQ infusion-pump issue remains an active FDA-classified recall linked to a software design problem. Continued restrictions could delay sales recovery and increase remediation costs or liability. (U.S. Food and Drug Administration)
Profitability is not yet matching the sales recovery: second-quarter adjusted EPS fell year on year and operating margin compressed, while part of the earnings benefit came from a one-off tariff refund. (VectorShift Research, Simply Wall St News)
Baxter’s significant indebtedness still consumes cash through debt service and limits its ability to fund growth and research. The need to prioritise deleveraging also leaves less cash for dividends or acquisitions in the near term. (Baxter, Baxter International Inc. 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
Baxter Financial Performance
Revenues and expenses
Baxter Earnings Performance
Company profitability
Upcoming events
Baxter News
AllArticlesVideos
Funds containing Baxter
AllEURGBPUSD
Fund name | Fund size | $BAX weighting |
|---|---|---|
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.20% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.20% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.19% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.14% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.